ADHD drug

Jul 31, 2026

Summary FDA approved Otsuka’s SIMTRIYO (centanafadine) on July 24, 2026, for ADHD treatment in patients aged ≥6 years weighing at least 20 kg. First-in-class norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), introducing a novel triple-mechanism approach. Approval backed by four Phase 3 trial...

Sep 04, 2018

Food and Drug Administration repudiates ADHD drug by Sunovion Sunovion’s ADHD drug for the treatment of attention-deficit hyperactivity disorder (ADHD) has not been accepted by the Food and Drug Administration, FDA. It is so because the drug for ADHD treatment in its current form needs additional clinical trials and...